Investorideas.com Newswire

Investorideas.com Newswire
Be one of the most talked about companies (stocks) on social media

Investorideas.com newswire, biotech stocks and industry

Wednesday, May 18, 2011

Pharma News; BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) To Present at Two Upcoming Investor Conferences

LINCOLNSHIRE, Ill. - May 18, 2011 (Investorideas.com newswire) - BioSante Pharmaceuticals, Inc. (NASDAQ:BPAX) will be presenting at two upcoming investors conferences on May 24, 2011.
Stephen M. Simes, BioSante's president & CEO, will speak on May 24, 2011 at 11:00 am London time at the UBS Global Specialty Pharmaceutical Conference being held on May 24-25, 2011 at UBS offices in London. A live audio webcast of Mr. Simes' remarks may be accessed at: http://cc.talkpoint.com/ubsx001/052411a_im/?entity=12_P5QEHBK. The webcast will be archived after the live event and will be available for 180 days.
Phillip B. Donenberg, BioSante's senior vice president of finance and CFO, will speak on May 24, 2011 at 11:30 am PT at the 7th Annual Spring Growth Stock Conference hosted by Security Research Associates, Inc. The conference will be held on Tuesday, May 24th at the Omni Hotel in San Francisco.
Both speakers will provide an overview of the BioSante, as well as an update on the LibiGel� (testosterone gel) Phase III clinical development program.
About BioSante Pharmaceuticals, Inc.
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante's lead products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment. BioSante also is developing a portfolio of cancer vaccines, four of which have been granted Orphan Drug designation, and are currently in several Phase II clinical trials. Other products in development are Bio-T-Gel™, a testosterone gel for male hypogonadism licensed to Teva Pharmaceuticals and an oral contraceptive in Phase II clinical development using BioSante patented technology. The company also is seeking opportunities for its other technologies. Additional information is available online at: www.biosantepharma.com.
Contact:
BioSante Pharmaceuticals
For Investors:
The Trout Group LLC
Tricia Swanson
(646) 378-2953
tswanson@troutgroup.com
or
For Media:
McKinney/Chicago
Alan Zachary
(312) 944-6784 ext. 316
azachary@mckinneychicago.com

Disclosure, Disclaimer/ BPAX is a paid advertising client on Investorideas.com (1000 per month).

No comments:

Post a Comment